Myocardial InfarctionSingHEARTNCT02791152
Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People
An observational study of Myocardial Infarction, run by National Heart Centre Singapore at 1 site in Singapore.
Trial summary
A prospective cohort of relatively healthy individuals, using comprehensive clinical information, advanced imaging (including cardiac MRI), cardiovascular exercise physiology, metabolomics and genetic analysis. Read more about this study
- Who is it for?
- Ages 21 to 69 yearsHealthy volunteers can take part
- Conditions the study is for
- Myocardial Infarction
- How many people
- 1,000 participants
- Where
- 1 siteSingapore
- Study dates
- Oct 2015to Dec 2036
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 69 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy volunteers age between 21 to 69 years old, Singapore citizens
Who may be able to join
- Men and women age 21-69 years
Who cannot join
- Previous myocardial infarction (MI). This will include ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI)
- Known coronary artery disease - prior coronary revascularization
- Known documented peripheral arterial disease
- Previous stroke
- Stroke is defined as new focal neurological deficit persisting more than 24hours21.
- More than ongoing use of 2 or more anti-hypertensive agents
Show all 16Show fewer
- Prior history of cancer (excludes pre-cancerous lesions)
- Expected life expectancy less than 1 year
- Known definite diabetes mellitus or on treatment for diabetes mellitus
- Known autoimmune disease or genetic disease
- Known endocrine disease on treatment
- Psychiatric illness
- Asthma or chronic lung disease requiring long term medications or oxygen
- Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV
- Inability to comply with study protocol
- Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
National Heart Centre Singapore
Singapore, Singapore, 169609
Khung Keong Yeo, MBBS, 67048963
Khung Keong Yeo, MBBS
About this study
Official title: SingHEART: Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People
A prospective cohort of relatively healthy individuals, using comprehensive clinical information, advanced imaging (including cardiac MRI), cardiovascular exercise physiology, metabolomics and genetic analysis. These findings will be correlated with adverse clinical outcomes including death, stroke and myocardial infarction. In selected cases, follow-up imaging and biomarker samples will also be obtained. These studies will enable us to begin to address a critical gap in our knowledge as to how best to interpret the very large amount of cardiovascular tests done in Singapore and how to better to predict outcomes and manage healthcare costs in our local populations
Read the detailed description
SingHEART sub-study will collect the following data types or perform the following investigations:
- Demographic and clinical characteristics data.
- Basic blood investigations. Basic blood investigations include: FBC, CRP, renal panel, random glucose, LFT, fasting lipids, ESR, CRP,
- Perform a single baseline cardiac MRI (already consented and obtained as part of the primary study).
- ECG
- Calcium score
- Biobanking (whole blood, plasma and serum, already performed as part of the primary study)
- Exercise and physical activity tracker over two 1-week periods
- Ambulatory BP monitoring over two 24-48H periods
- Conditions
- Myocardial Infarction
- Medical subject headings
- Myocardial Infarction
What is being measured
The primary outcome is the main question the study is designed to answer.
First cardiovascular event
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2016 (estimated)
- Study startOct 2015
- Primary completionDec 2036 (estimated)
- Study completionDec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Heart Centre Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yeo Khung Keong, MBBS, Principal investigator, National Heart Centre Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02791152
- Sponsor's protocol ID
- 2015/2601
- Acronym
- SingHEART
- Status last verified
- Sep 2015
- First submitted
- 31 May 2016
- Last updated
- 6 Jun 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Publications
Bylstra Y, Lim WK, Teo JX, Menezes M, Hodgson J, Yap F, Chambers JC, Yeo KK, Tan P, Amor DJ, Jamuar SS. Unexpected genotypes associated with severe paediatric conditions identified in a healthy population cohort. Eur J Hum Genet. 2026 Mar;34(3):368-378. doi: 10.1038/s41431-025-02009-2. Epub 2026 Jan 10.
PubMed 41520097Bylstra Y, Lim WK, Kam S, Tham KW, Wu RR, Teo JX, Davila S, Kuan JL, Chan SH, Bertin N, Yang CX, Rozen S, Teh BT, Yeo KK, Cook SA, Jamuar SS, Ginsburg GS, Orlando LA, Tan P. Family history assessment significantly enhances delivery of precision medicine in the genomics era. Genome Med. 2021 Jan 7;13(1):3. doi: 10.1186/s13073-020-00819-1.
PubMed 33413596